These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 19200857

  • 1. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F, Kieseier BC.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract] [Full Text] [Related]

  • 2. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B, Tremlett H.
    Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408
    [No Abstract] [Full Text] [Related]

  • 3. New options for early treatment of multiple sclerosis.
    Tintoré M.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [Abstract] [Full Text] [Related]

  • 4. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 01; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 5. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 6. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J, Lublin FD.
    Adv Neurol; 2006 Feb 01; 98():257-71. PubMed ID: 16400838
    [No Abstract] [Full Text] [Related]

  • 7. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.
    Neurodegener Dis; 2008 Feb 01; 5(1):32-7. PubMed ID: 18075273
    [Abstract] [Full Text] [Related]

  • 8. 'Time is brain' also in multiple sclerosis.
    Freedman MS.
    Mult Scler; 2009 Oct 01; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract] [Full Text] [Related]

  • 9. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS.
    Adv Neurol; 2006 Oct 01; 98():273-92. PubMed ID: 16400839
    [Abstract] [Full Text] [Related]

  • 10. Azathioprine and methotrexate in multiple sclerosis.
    Fernández O, Fernández V, De Ramón E.
    J Neurol Sci; 2004 Aug 15; 223(1):29-34. PubMed ID: 15261557
    [Abstract] [Full Text] [Related]

  • 11. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
    Prescrire Int; 2009 Dec 15; 18(104):252. PubMed ID: 20025092
    [No Abstract] [Full Text] [Related]

  • 12. Mitoxantrone in multiple sclerosis.
    Neuhaus O, Kieseier BC, Hartung HP.
    Adv Neurol; 2006 Dec 15; 98():293-302. PubMed ID: 16400840
    [No Abstract] [Full Text] [Related]

  • 13. Copolymer 1: an off-beat drug development story.
    Scheindlin S.
    Mol Interv; 2004 Feb 15; 4(1):6-9. PubMed ID: 14993470
    [No Abstract] [Full Text] [Related]

  • 14. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [Abstract] [Full Text] [Related]

  • 15. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G, Wipfler P, Ladurner G, Kraus J.
    Drug Discov Today; 2008 Dec 01; 13(23-24):1013-25. PubMed ID: 18775508
    [Abstract] [Full Text] [Related]

  • 16. Futility of the autoimmune orthodoxy in multiple sclerosis research.
    Behan PO.
    Expert Rev Neurother; 2010 Jul 01; 10(7):1023-5. PubMed ID: 20586684
    [No Abstract] [Full Text] [Related]

  • 17. Is natalizumab overshooting its rebound?
    Fox RJ, Kappos L.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1073-4. PubMed ID: 18362270
    [No Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H, Hohlfeld R.
    Neurology; 2009 Mar 17; 72(11):1008-15. PubMed ID: 19289741
    [Abstract] [Full Text] [Related]

  • 19. [Clinical and MRI effects of Glatirameracetate].
    Nervenarzt; 1999 Aug 17; 70(8 Suppl):1-8. PubMed ID: 10511871
    [No Abstract] [Full Text] [Related]

  • 20. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D, Sela M, Arnon R.
    Isr J Med Sci; 1997 Apr 17; 33(4):280-4. PubMed ID: 9347880
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.